OCIAD2
Reactivity: Human
WB, ELISA, IF
Host: Rabbit
Polyclonal
unconjugated
Application Notes
ELISA. Western blot: 0.5 - 1 μg/mL. Immunoflouescence. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
PBS containing 0.02 % sodium azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
-20 °C
Storage Comment
Store the antibody (in aliquots) at -20 °C.
Target
OCIAD2
(OCIA Domain Containing 2 (OCIAD2))
Alternative Name
OCIAD2
Background
OCIAD2 was identified by its sequence similarity with OCIAD1, and together OCIAD1 and OCIAD2 form the OCIA domain family. OCIAD2 mRNA was found to be expressed at higher levels in invasive adenocarcinoma mixed subtype with bronchioloalveolar carcinoma component (BAC) of the lung. Loss of OCIAD2 expression was significantly correlated with lymphatic invasion, blood vessel invasion, and lymph node metastasis, indicating that OCIAD2 may play a role in cell adhesion and prevention of cell migration. While the function of OCIAD2 is still unknown, its expression in adenocarcinoma with BAC component is significantly associated with a favorable prognosis and may serve as a marker for selecting tumors that are treatable by limited surgery.Synonyms: OCIA domain-containing protein 2, Ovarian carcinoma immunoreactive antigen-like protein